Raymond James analyst Lawrence Keusch maintained a Buy rating on Becton Dickinson (NYSE:BDX) And Company on Friday, setting a price target of $282, which is approximately 10.07% above the present share price of $256.21.
Keusch expects Becton Dickinson And Company to post earnings per share (EPS) of $0.36 for the first quarter of 2021.
The current consensus among 6 TipRanks analysts is for a Moderate Buy rating of shares in Becton Dickinson, with an average price target of $280.17.
The analysts price targets range from a high of $297 to a low of $265.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $4.78 billion and a net profit of $337 million. The company's market cap is $74.52 billion.
According to TipRanks.com, Raymond James analyst Lawrence Keusch is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 7.9% and a 68.82% success rate.
Becton, Dickinson & Co. is a medical technology company. The firm engages in the development, manufacture and sale of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. It operates through the following segments: BD Medical, BD Life Sciences and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect infectious diseases, healthcare-associated infections and cancers. The BD Interventional segment provides vascular, urology, oncology and surgical specialty products to hospitals, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via Homecare business. The company was founded in 1897 and is headquartered in Franklin Lakes, NJ.